11 registrations that name fisetin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 11 registrations
Status
Phase
28US sites across 8 states
1
2 to 4
5 to 19
20 or more
All 11 registrations
RecruitingNCT05758246
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Phase 2
University of Minnesota
About 220 people
Started Aug 23, 2023
In plain words A Phase 2 study of fisetin in people 65 and older, run by University of Minnesota. It plans to enroll about 220 people at 10 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older. Conditions: Sepsis; Acute Infection; Organ Failure.
Age >=65 years
Primary diagnosis of acute infection (per investigator judgment)
SOFA >1
Admission order to the hospital
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fisetin-dose 1; Fisetin-dose 2; Placebo
Registered summary
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. The full summary is on the listing.
Where, as registered
10 US sites in 4 states.
RecruitingNCT05595499
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Phase 2
Jonsson Comprehensive Cancer Center
About 88 people
Started Mar 27, 2023
In plain words A Phase 2 study of fisetin in female participants of any age, run by Jonsson Comprehensive Cancer Center. It plans to enroll about 88 people at 7 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants of any age. Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8.
Women who are postmenopausal at the start of study treatment.
Women aged: >= 60 years OR
Women aged < 60 years AND one of the following conditions is met:
They have not had any menstrual periods for at least 12 months in the absence of exogenous hormonal treatments, chemotherapy, and/or tamoxifen AND have serum estradiol and follicle-stimulating hormone (FSH) levels confirmed as being within…
14 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. The full summary is on the listing.
Where, as registered
7 US sites in 1 state.
RecruitingNCT06113016
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Phase 2
Jonsson Comprehensive Cancer Center
About 164 people
Started Jul 23, 2024
In plain words A Phase 2 study of fisetin in female participants of any age, run by Jonsson Comprehensive Cancer Center. It plans to enroll about 164 people at 6 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants of any age. Conditions: Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Early Stage Breast Carcinoma.
Women who are postmenopausal at the start of study treatment
Postmenopausal status will be established as follows: Women who are 50 years or older and who are not menstruating for greater than 12 months will be considered postmenopausal.
Women with a diagnosis of early-stage breast cancer (stage I, II, III) treated with neo/adjuvant chemotherapy within 12 months of starting study treatment
No evidence of active/recurrent breast cancer or other serious chronic illnesses
10 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. The full summary is on the listing.
Where, as registered
6 US sites in 1 state.
RecruitingNCT06819254
Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
Phase 4
Wake Forest University Health Sciences
About 60 people
Started Dec 9, 2025
In plain words A Phase 4 study of fisetin in people 65 and older, run by Wake Forest University Health Sciences. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older; healthy volunteers accepted. Conditions: Fatigue.
Self-reported history of cancer diagnosed > 12 months prior to enrollment excluding non-melanoma skin cancer with no evidence of disease at enrollment.
Eligible solid tumor cancer types include Stage 1-3 breast, lung, head and neck, colorectal, anal, prostate, melanoma, bladder/ureteral, esophageal, gastric, pancreatic, kidney, liver/biliary, uterine, cervical, ovarian, sarcoma.
Eligible hematologic malignancies include lymphoma any subtype any stage in remission, multiple myeloma in remission, leukemia any subtype in remission.
Eligible prior cancer treatment modalities include surgery, radiation, chemotherapy, hormonal therapies, immunotherapy, biologic therapies.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fisetin followed by Placebo; Placebo followed by Fisetin
Registered summary
The purpose of this study is to find out if taking a Fisetin supplement can decrease fatigue among older cancer survivors.
Where, as registered
1 US site in 1 state.
RecruitingNCT07676435
Ongoing Lung Decline With Age Intensified Response
Phase 2
Cedars-Sinai Medical Center
About 40 people
Started Jun 17, 2026
In plain words A Phase 2 study of fisetin in people 60 and older, run by Cedars-Sinai Medical Center. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older; healthy volunteers accepted. Conditions: Age-Related Lung Function Decline.
Adults aged 60 years and older who are physically capable of participating in study procedures;
Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (<5-pound change);
No blood donation within 2 months before screening; absence of unstable chronic disease;
Willing to maintain baseline activity level throughout the study;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fisetin; Placebo
Registered summary
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Where, as registered
1 US site in 1 state.
RecruitingNCT06399809
Fisetin to Reduce Senescence and Mobility Impairment in PAD
Phase 2
Northwestern University
About 34 people
Started Sep 30, 2024
In plain words A Phase 2 study of fisetin in people 50 and older, run by Northwestern University. It plans to enroll about 34 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Peripheral Arterial Disease; Aging; Peripheral Vascular Diseases; Walking, Difficulty; Claudication.
An ankle brachial index (ABI) less than or equal to 0.90 at baseline.
Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the…
An ABI of greater than 0.90 and less than or equal to 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included.
The exclusion criteria are on the listing.
What it tests, as registered
Fisetin; Placebo
Registered summary
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07025226
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
Early phase 1
Mayo Clinic
About 30 people
Started Aug 12, 2025
In plain words An early phase 1 study of fisetin in people 18 and older, run by Mayo Clinic. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glioma.
Age ≥ 18 years
Prior diagnosis of a glioma treated with chemotherapy and/or radiation with stable disease based on Response Assessment in Neuro-Oncology (RANO) criteria
Must have IDH-mutant OR MGMT-methylated glioma
NOTE: Patients with any radiographic evidence of residual disease are eligible
20 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Biospecimen Collection; Dasatinib; Fisetin; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Quercetin; Temozolomide; Topoisomerase-1 Inhibitor LMP744; Single Agent Therapy
Registered summary
This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous tumor lysate particle only (TLPO) vaccine work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07195318
Fisetin Supplementation for Healthy Aging
No phase
Ove Andersen
About 120 people
Started Sep 24, 2025
In plain words A study of fisetin in people 50 and older, run by Ove Andersen. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older; healthy volunteers accepted. Conditions: Healthy.
Middle-aged or older adult (≥50 years),
Able to cooperate cognitively,
Able to read and understand Danish,
The exclusion criteria are on the listing.
What it tests, as registered
Fisetin; Placebo
Registered summary
There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT06796374
A Comparison of Fisetin Kinetics in Young and Old Adults
No phase
University Medicine Greifswald
About 80 people
Starts Mar 31, 2026 (estimated)
In plain words A study of fisetin in people 18 and older, run by University Medicine Greifswald. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Pharmacokinetic Study in Healthy Volunteers.
any sex
age between 18 and 30 years or ≥ 65 years
understands the study purpose and design
contractually capable and provides signed informed consent form
2 more inclusion criteria and the exclusion criteria are on the listing.
This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers: Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40) The purpose of this study is: 1. To describe the fisetin kinetics after a single dose oral administration in older age. 2. To compare the fisetin kinetics after a single dose oral administration in old and young age. FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. The full summary is on the listing.
Where, as registered
No US site; Germany (1).
RecruitingNCT06431932
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
Phase 1 and 2
Ove Andersen
About 60 people
Started Mar 24, 2026
In plain words A Phase 1 and 2 study of fisetin in people 20 and older, run by Ove Andersen. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older; healthy volunteers accepted. Conditions: Multimorbidity; Healthy.
Aged 20-35 years
suPAR levels <3.5 ng/mL (± 15% corresponding to assay variation)
Able to cooperate cognitively
Able to read and understand Danish
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fisetin; Placebo
Registered summary
The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models. We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
Not yet recruitingNCT07871162
Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial
Phase 2
University of Colorado, Boulder
About 136 people
Starts Nov 2026 (estimated)
In plain words A Phase 2 study of fisetin in people 65 and older, run by University of Colorado, Boulder. It plans to enroll about 136 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older; healthy volunteers accepted. Conditions: Aging; Endothelial Dysfunction; Cellular Senescence.
Age 65 years or older
Women must be postmenopausal
Body mass index (BMI) <40 kg/m2
Willing to accept random assignment
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fisetin; Placebo
Registered summary
Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence. The study will also evaluate safety, tolerability and adherence with fisetin treatment.